Caught in a vortex of economic slowdown and competitive concerns
05/12/25 -"In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation metrics. This adjustment mitigates the skewed impact of ..."
Pages
65
Language
English
Published on
05/12/25
You may also be interested by these reports :
03/03/26
S&N delivered a healthy Q4 and broadly in-line FY25 performance, supported by recovery in Orthopaedics, strong Sports Medicine momentum, and ...
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...